Kite Pharma Inc. is kicking off its ZUMA-3 study, the third in what's soon to be a quartet of pivotal studies aimed at supporting regulatory approval of KTE-C19, its anti-CD19 chimeric antigen receptor (CAR) T-cell therapy and lead candidate.